DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Selumetinib sulfateis the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Selumetinib sulfate has one hundred and fifty-five patent family members in thirty-eight countries.
One supplier is listed for this compound.
Recent Clinical Trials for selumetinib sulfate
Identify potential brand extensions & 505(b)(2) entrants
|National Cancer Institute (NCI)||Phase 3|
|United States Department of Defense||Phase 2|
|Sarcoma Alliance for Research through Collaboration||Phase 2|
Pharmacology for selumetinib sulfate
|Drug Class||Kinase Inhibitor |
|Mechanism of Action||Mitogen-Activated Protein Kinase Kinase 1 Inhibitors |
Mitogen-Activated Protein Kinase Kinase 2 Inhibitors
|Country||Patent Number||Estimated Expiration|
|Spain||2628959||⤷ Free Forever Trial|
|Denmark||1968948||⤷ Free Forever Trial|
|Russian Federation||2004127926||⤷ Free Forever Trial|
|Israel||163995||⤷ Free Forever Trial|
|Israel||192224||⤷ Free Forever Trial|
|Japan||2012224649||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|1482932||PA2019007,C1482932||Lithuania||⤷ Free Forever Trial||PRODUCT NAME: BINIMETINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/18/1315 20180920|
|1482932||2019C/510||Belgium||⤷ Free Forever Trial||PRODUCT NAME: BINIMETINIB SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/18/1315 20180924|
|1482932||PA2019007||Lithuania||⤷ Free Forever Trial||PRODUCT NAME: BINIMETINIBAS BET KOKIOMIS FORMOMIS, KURIOMS TAIKOMA PAGRINDINIO PATENTO APSAUGA; REGISTRATION NO/DATE: EU/1/18/1315 20180920|
|1482932||CA 2019 00011||Denmark||⤷ Free Forever Trial||PRODUCT NAME: BINIMETINIB I ALLE FORMER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/18/1315 20180924|
|1482932||648||Finland||⤷ Free Forever Trial|
|1482932||122019000022||Germany||⤷ Free Forever Trial||PRODUCT NAME: BINIMETINIB EINSCHLIESSLICH BINIMETINIB IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES ODER SOLVATS; REGISTRATION NO/DATE: EU/1/18/1315 20180920|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.